Getting Started with AI in Pharma Revenue Management

In our previous article, we laid out the business case for AI in pharmaceutical revenue management: $356 billion in gross-to-net reductions flowing out of the industry annually, an estimated 2 to 3 percent of rebate value lost to formulary leakage alone, and a structural gap between what rules-based revenue management systems were built to handle and what today's contracting environment actually demands. The ROI opportunity is real, and it is large.

But for most manufacturers, the more pressing question is not whether to pursue this capability. It is how to start. What follows is a practical framework for sequencing the investment to demonstrate early wins, build organizational confidence, and avoid the pitfalls that have caused earlier AI deployments to underdeliver.

Phase 1: Identify and Quantify Your Highest-Value Pain Points

Before choosing a technology, start with a structured diagnostic of where manual effort and error rates are most concentrated. Formulary validation, chargeback dispute resolution, and government pricing reconciliation are the most common starting points, but the right answer will be specific to your contract portfolio, customer mix, and current operational model.

Quantify the current cost in concrete terms: analyst hours by workflow, error rates and their downstream financial impact, BPO spend, and IT workaround maintenance burden. This baseline serves two purposes. It identifies where to start, and it establishes the measurement framework for demonstrating ROI to internal stakeholders later. Finance and compliance will want to see demonstrated returns before scaling. That case is much easier to make when you have a pre-intervention baseline to compare against.

Phase 2: Capture the Institutional Knowledge Before You Automate

The single most common reason AI deployments underperform in pharma contract operations is that they attempt to automate workflows before encoding the operational knowledge that makes those workflows function. The logic in the system will only be as good as the logic that analysts are currently applying in Excel.

Before building agents, invest in structured knowledge capture. Document the exception types that recur most frequently, the resolution logic analysts apply, the payer and customer behaviors that require non-standard handling, and the data quality issues that routinely corrupt automated processing. Interview the senior analysts whose judgment currently carries the team. This documentation becomes the foundation for agent training and the benchmark for evaluating agent performance.

It is also, in its own right, a risk management exercise. If the most experienced person on your contract operations team left tomorrow, how much of what they know would leave with them?

Phase 3: Start With a Contained, High-ROI Pilot

Choose one workflow with clear inputs, clear outputs, measurable outcomes, and a known error rate. Formulary validation is often the right starting point. The data is structured, the expected outcomes are contractually defined, and the financial impact of errors is directly measurable. The MMIT-estimated 2 to 3 percent leakage figure means a manufacturer can calculate expected ROI before writing a single line of code.

Build the pilot to run in parallel with the existing manual process, not to replace it. This is important for two reasons. First, it allows direct comparison of agent performance against analyst performance, which is the only credible way to demonstrate accuracy in a compliance-sensitive environment. Second, it gives analysts the visibility they need to trust the system and, critically, to improve it. Compliance-sensitive environments require explainability, and explainability requires transparency about how the agent is reaching its conclusions. Analysts who can see what the system is doing, and flag when it is wrong, are your most valuable quality control mechanism in the early stages.

Phase 4: Scale With Operational Memory as the Core Asset

Once the pilot demonstrates performance parity or better, expand scope across both additional workflows and the agent's ability to learn from resolved exceptions. Every dispute resolved, every formulary validated, every chargeback corrected is training data for the next cycle. The system should be getting measurably smarter with each pass.

The goal is not to build a faster version of the current process. It is to build a system that gets progressively smarter about your specific market, your specific customers, and your specific contract structures. That distinction matters. Automation reduces cost. Intelligence creates advantage. The manufacturers who will be best positioned in five years are those who start building operational memory now, while their competitors are still reconciling exceptions in pivot tables.

At each stage, measure and communicate the ROI. Internal stakeholders across finance, compliance, IT, and commercial leadership will want to see demonstrated returns before committing to broader investment. A well-instrumented pilot that shows concrete margin recovery and operational cost reduction is the most effective path to that commitment.

Sequencing your phases correctly is necessary but not sufficient. Program structure is just as critical as execution. Three areas deserve deliberate attention as you set up your initiative: the principles your solution must satisfy, the governance model that will carry it forward, and a realistic timeline for what to expect.

Solution Success Principles

Not all AI platforms are suited to this environment. The requirements of pharma revenue management go well beyond general-purpose AI capabilities. When evaluating potential partners or build approaches, the following criteria matter most.

• Auditability and explainability: In a compliance-sensitive environment, outputs need to be traceable. Any system that cannot explain why it flagged an exception, or how it reached a given conclusion, is a liability rather than an asset.
• Multi-agent orchestration: Single-model deployments are insufficient for the complexity of the revenue management workflows. The right architecture uses coordinated agents for extraction, normalization, validation, exception detection, dispute drafting, and escalation — each with a defined scope and shared operational memory layer.
• Incremental learning: The system should improve demonstrably with each cycle. Neglecting to build operational memory from day one is a strategic misstep.
• Domain specificity: General-purpose AI platforms require extensive configuration to handle the nuances of pharma contract operations. Partners who have built natively for this environment will reach production-quality performance faster.
• Time-ordered data architecture: Pharma contract operations data is relational and time-ordered, not primarily semantic. Systems built on vector search and retrieval-augmented generation are well-suited to document similarity tasks but not to the kind of pattern recognition across quarterly cycles that this environment demands.

Team Governance Architecture

Technology selection and implementation sequencing matter. But the most common reason AI deployments stall is not technical — it is organizational. Manufacturers who succeed treat AI in revenue management as a business transformation initiative, not an IT project.

Best practice is to designate a product manager, either in the technology organization or in the business, who can serve as the nexus between operational leaders, IT, finance, and compliance. This person is not responsible for configuring the systems, but rather for defining what success looks like. This includes clear business outcomes, measurable KPIs tied to margin recovery, operational cost reduction, and a structured feedback loop between the system's performance and the team whose workflows it supports.

The analogy to drug development is useful here. No one launches a clinical program without a primary endpoint. AI in contract operations deserves the same discipline. Without a defined North Star, specific and measurable outcomes, even technically successful deployments struggle to earn the organizational buy-in needed to scale.

AI transformation success depends far more on having the right people and processes in place than on the underlying technology itself. Getting the governance right is of utmost importance.

A Realistic Timeline

For a manufacturer starting from scratch, a reasonable timeline looks something like this. The first 60 to 90 days should be devoted to the diagnostic and knowledge capture phases: identifying the highest-value workflows, quantifying current costs and error rates, and documenting the institutional knowledge that will seed the initial agents. The following 90 days should be the contained pilot, running in parallel with the existing process. By the end of the first six months, a well-run pilot should be able to demonstrate both performance accuracy and initial ROI. Scaling from there is a function of organizational appetite and available workflows.

None of this requires a complete transformation of the existing technology stack. The Revenue Management System stays in place. The pilot adds an intelligence layer on top of it, starting in one workflow, demonstrating value, and expanding from there. That is the architecture that works in practice, and it is the one that will earn the trust of compliance, finance, and IT stakeholders who will reasonably need to see it work before they champion broader investment.

The Window for Competitive Advantage Is Open, But Not Indefinitely

Pharma manufacturers have spent decades accumulating operational knowledge about how their markets work. That knowledge has never been treated as the strategic asset it is. AI gives manufacturers a way to finally capture it, codify it, and deploy it at scale. The manufacturers who move now will build operational memory advantages that compound over time. Those who wait will be playing catch-up against competitors who have two or three years of learned exceptions, validated patterns, and encoded institutional knowledge already working in their favor.

The path is practical, the ROI is concrete, and the starting point is closer than most teams realize. The first step is simply deciding that the knowledge your best analysts carry in their heads is worth more than your current system gives you any way to capture.